← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ayuvis Research, Inc.
Fort Worth, TX
$4,447,445
Total funding
4
Grants
Funding over time
peak $1.2M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,447,445 · 4
By mechanism
R44$3,623,043 · 2
R61$550,576 · 1
R43$273,826 · 1
Investigators at Ayuvis Research, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$1,109,134
R44 · FY2022 · HD
Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates$895,365
R44 · FY2024 · HD
Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates$712,481
R44 · FY2025 · HD
A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$702,096
R44 · FY2023 · HD
Phase-1 Healthy adult human safety and pharmacokinetic study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in at-risk pre-term infants$279,788
R61 · FY2024 · HL
Novel multifunctional oligosaccharide for treating sepsis and severe sepsis.$273,826
R43 · FY2017 · AI
Phase-1 Healthy adult human safety and pharmacokinetic study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in at-risk pre-term infants$270,788
R61 · FY2023 · HL
A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$203,967
R44 · FY2023 · HD